Clinical Study of Urinary Kallidinogenase in the Treatment of Progressive Cerebral Infarction
Abstract
Objective: To evaluate the efficacy and safety of Urinary kallidinogenase in the treatment of progressive cerebral infarction. Method: 104 cases of patients with acute cerebral infarction were randomly divided into treatment group and control group; where control group (52 cases) patients on with only basic medicine, while treatment group (52 cases), besides the basic medicine, patients will on urinary kallidinogenase 0.15 PNAU + 0.9% normal saline 100 mL intravenous injection, 1 times per day, and continuous for 14 days. The degree of neurological impairment (NIHSS) was assessed before and after treatment, and the changes of blood pressure were monitored. The liver, renal function, fibrinogen, platelet, and the adverse reactions were recorded and followed up in three month. Results: After treatment, NIHSS scores of the both groups were decreased (p < 0.05), however, total effective rate for treatment group were better than control group (p < 0.05). Conclusion: Urinary kallidinogenase is safe and effective in the treatment of progressive cerebral infarction.
References
2. Zhong Y. Clinical neurological impairment score. Chinese Journal of Neurology. 1996;29(6):381.
3. Deng BM, Liu Y, et al. Urinary Kallidinogenase in the treatment of acute cerebral infarction clinical observation. Journal of Brain and Nervous Diseases. 2009;17(2):104‒105.
4. Wen DS, Wu ZW, et al. Urinary kallidinogenase treatment acute progressive cerebral infarction curative effect observation. Chinese Journal of Stroke. 2011;17(2):113‒114.
5. Cao J. Kinin in stroke cardiovascular and renal disease. Exp Hysiol. 2005;90:291‒298.
6. Wang L, Zhang Y. The clinical effect of acute cerebral infarction treated by Urinary Kallidinigenase. Chinese Journal of Nervous and Mental Diseases. 2011;36(10):627‒629.
Copyright (c) 2013 Binghui Fan, Weidong Li
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
